Login to Your Account

Neostem adds 'neo' pipeline with CSC acquisition

By Marie Powers
Staff Writer

Monday, April 14, 2014
Neostem Inc. set its sights on the hot cancer immunotherapy market with an agreement to acquire California Stem Cell Inc. (CSC) through a stock transaction. The New York-based cell therapy company moves melapuldencel-T, an autologous stem cell immune-based therapy, to the head of the class and takes on the challenge of a phase III trial with the CSC buy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription